Product Sales Commenced and Targeted Advertising Campaign Initiated
TEMPE, Ariz., Mar 30, 2004 /PRNewswire-FirstCall via COMTEX/ -- Nutraceutical company, Health Enhancement Products, Inc. (OTC: HEPI) today announced the official launch of the Company's flagship product, ProAglaZyme. Sales of ProAlgaZyme have also commenced through several U.S. distributors, as well as through the Company's website, www.heponline.com.
The Company's targeted advertising campaign will focus on people with varying, serious illnesses, particularly those with weakened immune systems. The majority of the advertising campaign will be placed on high profile health and medical radio talk shows with audiences that closely match the Company's targeted consumer. Health Enhancement Products has also arranged for several live interviews. As a secondary phase of the advertising campaign, the Company has started marketing and selling ProAlgaZyme through Internet advertising. Initial ads will run via powerful, highly visited online sites such as FoxNews.com, NewsMax.com, and Politics.com, among others.
About Health Enhancement Products, Inc.
Health Enhancement Products, Inc. (OTC: HEPI) is a nutraceutical company directed specifically at the development and marketing of supplementary health-enhancing products using only pure, all-natural and herbal extracts. In particular, Health Enhancement's products use beneficial herbal extracts, vitamins, minerals, and botanical extracts in varying combinations to address common or specific illnesses.
The Company's primary product is ProAlgaZyme, an immune system enhancer that is produced from algae grown in 100% purified water. The algae produces an enzyme as a means of protecting itself from exposure to outside disease and harmful bacteria. The enzyme is then drawn off, filtered, tested and bottled for consumption. Recent clinical trials performed by the Company have indicated that ProAlgaZyme may increase and activate the white blood cells in individuals whose white cells are low or inactive, in effect enhancing the immune system. Heath Enhancements is currently doing internal clinical trials on several illnesses and diseases with ProAlgaZyme.
This press release may contain forward-looking statements. The words "estimate," "possible" and "seeking" and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.